Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?
Authors:
- Peter M. WehmeierPWPeter M. Wehmeier
- Alexander SchachtASAlexander Schacht
- Fredrik UlberstadFUFredrik Ulberstad
- Martin LehmannMLMartin Lehmann
- Christian Schneider-FreseniusCSChristian Schneider-Fresenius
- Gerd LehmkuhlGLGerd Lehmkuhl
- Ralf W. DittmannRDRalf W. Dittmann
- Tobias BanaschewskiTBTobias Banaschewski
- 1 October 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 32 (5) , 653-660
Abstract
The primary objective of this study was to evaluate the efficacy of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD)–related symptoms assessed as standard variables of a computer-based continuous performance test (cb-CPT) combined with a motion-tracking (MT) device. This was a 2-arm, 8-week, randomized, double-blind, placebo-controlled study in patients with ADHD (6–12 years). Therapy with ATX started with 0.5 mg/kg per day for 1 week, followed by 7 weeks on the target dosage of 1.2 mg/kg per day. Primary outcomes were cb-CPT/MT standard scores after 8 weeks using mixed models for repeated measurements. In addition, investigator-rated ADHD Rating Scale (ADHD-RS), Weekly Ratings of Evening and Morning Behavior (WREMB), and Clinical Global Impression – Severity-ADHD (CGI-S-ADHD) scores were assessed. Of 128 patients randomized, 125 were evaluated (ATX/placebo: 63/62). Baseline characteristics were comparable in both groups (overall, 80.2% boys; mean [SD] age, 9.0 [1.79] years; comorbid Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis, 40.0% oppositional defiant disorder/conduct disorder; prior stimulant treatment, 24.8%; ADHD-RS total score, 36.99 [11.56]). At week 8, all cb-CPT/MT q-scores were significantly reduced versus placebo (all P < 0.001) with effect sizes (ESs) of reaction time (RT) variation (ES = 0.71), mean RT (ES = 0.41), number of microevents (ES = 1.00), commission error rate (ES = 0.50), distance of movement (ES = 0.90), area of movement (ES = 1.08), omission error rate (ES = 0.70), time active (ES = 0.69), motion simplicity (ES = 0.38), and normalized variance of RT (ES = 0.50). Secondary end points also improved significantly in favor of ATX: ADHD-RS (total score ES = 1.30, P < 0.001; hyperactivity/impulsivity subscore ES = 1.37, P < 0.001; inattention subscore ES = 1.07, P < 0.001), WREMB (total score ES = 1.00, P < 0.001; morning subscore ES = 0.59, P = 0.002; evening subscore ES = 1.02, P < 0.001), CGI-S-ADHD (ES = 1.11, P < 0.001). The results of this study show that ATX for 8 weeks significantly reduced ADHD-related symptoms as measured by the cb-CPT/MT.Keywords
This publication has 34 references indexed in Scilit:
- Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attentionBehavioral and Brain Functions, 2010
- Toward a New Understanding of Attention-Deficit Hyperactivity Disorder PathophysiologyCNS Drugs, 2009
- Morning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studiesChild and Adolescent Psychiatry and Mental Health, 2009
- Utility of Objective Measures of Activity and Attention in the Assessment of Therapeutic Response to Stimulants in Children with Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2008
- Is OPTAx™ useful for monitoring the effect of stimulants on hyperactivity and inattention?European Child & Adolescent Psychiatry, 2007
- CorrgramsThe American Statistician, 2002
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Research on executive function in a neurodevelopmental context: Application of clinical measuresDevelopmental Neuropsychology, 1996
- Subtype analysis of commission errors on the continuous performance test in childrenDevelopmental Neuropsychology, 1991
- Objectively Measured Hyperactivity—I. Comparison With Normal ControlsThe Journal of Clinical Pharmacology, 1985